- Home
- MQ vs TARS Comparison
MQ vs TARS Comparison
Compare MQ & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MQ
- TARS
- Stock Information
- Founded
- MQ 2010
- TARS 2016
- Country
- MQ United States
- TARS United States
- Employees
- MQ N/A
- TARS N/A
- Industry
- MQ Computer Software: Prepackaged Software
- TARS Medicinal Chemicals and Botanical Products
- Sector
- MQ Technology
- TARS Health Care
- Exchange
- MQ Nasdaq
- TARS Nasdaq
- Market Cap
- MQ 1.9B
- TARS 2.0B
- IPO Year
- MQ 2021
- TARS 2020
- Fundamental
- Price
- MQ $3.69
- TARS $47.84
- Analyst Decision
- MQ Hold
- TARS Strong Buy
- Analyst Count
- MQ 15
- TARS 6
- Target Price
- MQ $5.50
- TARS $56.00
- AVG Volume (30 Days)
- MQ 4.4M
- TARS 460.8K
- Earning Date
- MQ 02-26-2025
- TARS 02-25-2025
- Dividend Yield
- MQ N/A
- TARS N/A
- EPS Growth
- MQ N/A
- TARS N/A
- EPS
- MQ 0.03
- TARS N/A
- Revenue
- MQ $490,027,000.00
- TARS $129,621,000.00
- Revenue This Year
- MQ N/A
- TARS $921.89
- Revenue Next Year
- MQ $15.46
- TARS $85.83
- P/E Ratio
- MQ $137.42
- TARS N/A
- Revenue Growth
- MQ N/A
- TARS 801.96
- 52 Week Low
- MQ $3.37
- TARS $20.08
- 52 Week High
- MQ $7.36
- TARS $57.28
- Technical
- Relative Strength Index (RSI)
- MQ 45.67
- TARS 39.21
- Support Level
- MQ $3.58
- TARS $49.86
- Resistance Level
- MQ $3.97
- TARS $53.22
- Average True Range (ATR)
- MQ 0.13
- TARS 2.44
- MACD
- MQ 0.00
- TARS -0.56
- Stochastic Oscillator
- MQ 29.11
- TARS 7.09
About MQ Marqeta Inc.
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.